Evolution and governance of the biotechnology and pharmaceutical industry of China

Mathematics and Computers in Simulation

Volumn 79, Issue 9, 2009, Pages 2947-2956

  Wang, Kai ^a   Hong, Jin ^a   Marinova, Dora ^b   Zhu, Liang ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b CURTIN UNIVERSITY   (Australia)

Author keywords

Actor Networks theory (ANT); Biotechnology and pharmaceutical industry; Evolution; Governance

Indexed keywords

ACTOR-NETWORKS THEORY (ANT); BIOTECHNOLOGY INDUSTRY; EVOLUTION; EVOLVING NETWORKS; GOVERNANCE; HIGH-SPEED; MANAGEMENT PRACTICES; PHARMACEUTICAL INDUSTRY; RESEARCH AND DEVELOPMENT; SCIENCE AND TECHNOLOGY POLICY; SOCIAL CONTEXT; THEORETICAL FRAMEWORK;

BIOTECHNOLOGY; DRUG PRODUCTS PLANTS;

INDUSTRY;

EID: 67349261410     PISSN: 03784754     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.matcom.2008.09.001     Document Type: Article

References (25)

1. Biagioli M. The Science Studies Reader. Routledge (1999) 137-160
2. Breithaupt H. China's leap forward in biotechnology. EMBO Reports 4 (2003) 111-113
3. In: Callon M., et al. (Ed). Mapping the Dynamics of Science and Technology (1986), The Macmillan Press
4. Department of High Technology Industry Development of Commission of National Development Planning, and Chinese Academy of Bioengineering (DHTID). Report on Development of Chinese Bio-technology, 2002 (2003), Chemical Industry Press, Modern Bio-technology and Medical Science and Technology Centre, Beijing
5. H. Ding, Bio-industry R&D in China, Finpro Tekes China Silk Road Biotech Project, Finpro Shanghai, June (2007).
6. F. Fang, China Pharmaceutical Industry Report, http://www.researchchina.com/ (2006-2007).
7. Giesecke S. The contrasting roles of government in the development of biotechnology industry in the US and Germany. Research Policy 29 2 (2000) 205-223
8. Hall L., and Bagchi-Sen S. An analysis of firm-level innovation strategies in the US biotechnology industry. Technovation 27 (2007) 4-14
9. Hamer D.H., and Kung S. Biotechnology in China (1989), National Academy Press, Washington, DC pp. 3-16
10. Hara T. Innovation in the Pharmaceutical Industry (2003), Edward Elgar, Cheltenham, UK p. 292
11. Jiang Y., et al. Chinese pharmaceutical companies: an emerging industry. Drug Discovery Today 6 No. 12 (2001) 610-612
12. Li Z., et al. Health biotechnology in China-reawakening of a giant. Nature Biotechnology 22 Suppl. (2004)
13. Liu Y. Development of Biotechnology Industry and its Impacts in China (2006 December), SEPA, Paris
14. Needham J. Science and Civilisation in China (1954), Cambridge University Press, London
15. Pisano G. The governance of innovation: Vertical integration and collaborative arrangements in the biotechnology industry. Research Policy 20 3 (1991) 237-249
16. Powell W. Interorganizational collaboration and the locus of innovation: networks of learning in biotechnology. Administrative Science Quarterly 41 (1996) 116-145
17. Senker J. National innovation system, organizational learning and Industrial biotechnology. Technovation 16 5 (1996) 219-229
18. Springham D. Biotechnology the Science and the Business. second edition (1999), Harwood Academic Publishers
19. van Beuzekom B., and Arundel A. OECD Biotechnology Statistics-2006 (2006), OECD
20. Wang J.Z. The Research and Quality Control of Medical Bio-technology (2002), Science Press, Beijing
21. White S., and Liu X. Organizational processes to meet new performance criteria, Chinese pharmaceutical firms in transition. Research Policy 27 (1998) 369-383
22. Williams-Johns B., and Graham J. Actor-networks theory: a tool to support ethical analysis of commercial genetic testing. New Genetics and Society 22 3 (2003) 271-296
23. Wong G. Chinese biotech: the need for innovation and higher standards. Journal of Nature Biotechnology 24 (2006) 221-222
24. Yearley S. Making Sense of Science (2005), Sage Publications, London p. 226
25. Yeung G. The implications of WTO accession on the pharmaceutical industry in China. Journal of Contemporary China 11 32 (2002) 473-493